Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Gefitinib is currently the standard-of-care for patients with activating-EGFR mutant advanced
non-small cell lung cancer (NSCLC). However, ~30-40% patients are still nonresponsive, and
experience significantly varying duration of response and survival rate. Anlotinib is an
efficient multi-target tyrosine kinase inhibitor (TKI) that effectively block the migration
and proliferation of endothelial cells and reduce tumor microvascular density by targeting
VEGFRs, FGFRs, PDGFRs. It has been proved to be safe and effective in advanced lung cancer
after second-line standard chemotherapy failure, which can significantly extend the survival
of patients and approves as a third-line treatment for advanced NSCLC. Here, we prepared to
evaluate whether the combination of gefitinb and anlotinib can preferably improved survival
of untreated NSCLC with EGFR activating mutation.